Modulating Metabolism During Manufacturing to Improve Anti-Tumour Efficacy & Persistence of CAR-T Cell Therapies

Time: 3:00 pm
day: Day Two


  • Overview of MPC Therapeutics’ approach to target the mitochondrial pyruvate carrier (MPC) to reprogamme CAR-T cell metabolism
  • Discussing preclinical data showing MPC inhibition during manufacturing dramatically improves CAR-T cell survival and efficacy
  • Exploring challenges and opportunities in translating novel manufacturing processes targeting metabolism to the clinic